[Effects of a new histamine H2-receptor antagonist, ranitidine, on experimental acute gastric and duodenal ulcers (author's transl)].
Ranitidine at 100 to 200 mg/kg (i.d. or p.o.) potently inhibited the development of Shay ulcers, indomethacin- or phenylbutazone-induced gastric ulcers and histamine-carbachol-induced duodenal ulcers in rats. Ranitidine at 100 mg/kg (p.o.) also inhibited the development of water-immersion stress-induced gastric ulcers in rats, histamine-induced gastric and duodenal ulcers in guinea pigs, even though the inhibition rate remained within 70%. At that time, the gastric acid output in guinea pigs was reduced with some doses of the drug. Cimetidine at 100 to 200 mg/kg (p.o.) also inhibited the development of indomethacin-, phenylbutazone-, and water-immersion stress-induced gastric ulcers in rats and histamine-induced gastric and duodenal ulcers in guinea pigs. Shay ulcers and histamine-carbachol-induced duodenal ulcers in rats were not affected by cimetidine. Both ranitidine and cimetidine inhibited the gastric acid output in pylorus-ligated rats (7 hr); the maximal inhibition being 79.6% and 50.7% respectively. The mechanism by which ranitidine inhibits various experimental ulcers might be mainly the inhibition of gastric secretion. Gefarnate at 300 mg/kg (p.o.) significantly inhibited phenylbutazone-induced gastric ulcers in rats but had no effect on other ulcer models.
D000208:Acute Disease; D000818:Animals; D004353:Drug Evaluation, Preclinical; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005663:Furans / Q000494:pharmacology / Q000627:therapeutic use*; D005750:Gastric Juice / Q000378:metabolism; D006168:Guinea Pigs; D006635:Histamine H2 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011899:Ranitidine; D051381:Rats; D013276:Stomach Ulcer / Q000188:drug therapy*
D005663:Furans; D006635:Histamine H2 Antagonists; D011899:Ranitidine